This search looks for keywords in all of the website’s content. Search tips
Filter by
- Agenda(1902)
- Annex to CHMP highlights(367)
- Annual Report(91)
- Application withdrawal assessment report(276)
- Committee meeting report(882)
- COVID-19 vaccine safety update(71)
- Direct healthcare professional communication(121)
- EPAR - All authorised presentations(1975)
- EPAR - Amended Product Information(1)
- EPAR - Assessment report - Variation(2701)
- EPAR - Assessment report on maintenance of orphan designation - Initial authorisation(139)
- EPAR - Assessment report on maintenance of orphan designation - Post-authorisation(41)
- EPAR - Conditions imposed on member states for safe and effective use(112)
- EPAR - Full risk management plan(3)
- EPAR - Overview(1971)
- EPAR - Paediatric investigation plan compliance statement(88)
- EPAR - Procedural steps taken and scientific information after authorisation(1876)
- EPAR - Procedural steps taken before authorisation(484)
- EPAR - Product Information(1971)
- EPAR - Public assessment report(1546)
- EPAR - Risk-management-plan summary(1133)
- EPAR - Scientific conclusion(1353)
- EPAR - Scientific Discussion(504)
- EPAR - Scientific Discussion - Variation(188)
- EPAR - Steps taken after authorisation when a cutoff date has been used(170)
- Herbal - Call for data(293)
- Herbal - Herbal monograph(118)
- Herbal - HMPC assessment report(476)
- Herbal - HMPC opinion on a European Union herbal monograph(246)
- Herbal - List of references supporting the assessment report(462)
- Herbal - Overview of comments received during consultation(163)
- Herbal - Summary of assessment report for the public(120)
- Herbal – European Union herbal monograph(330)
- Herbal – European Union list entry(19)
- Leaflet(71)
- Maximum Residue Limits - Divergent opinion(2)
- Maximum Residue Limits - Opinion(88)
- Maximum Residue Limits - Report(803)
- Maximum Residue Limits - Summary of opinion(14)
- Medicine QA(456)
- Medicines under additional monitoring(22)
- Minutes(1247)
- Newsletter(298)
- Opinion outside EU - All presentations(14)
- Opinion outside EU - Assessment report - Variation(9)
- Opinion outside EU - Medicine questions and answers(1)
- Opinion outside EU - Procedural steps taken and scientific information after opinion(11)
- Opinion outside EU - Procedural steps taken before opinion(3)
- Opinion outside EU - Product information(15)
- Opinion outside EU - Public assessment report(12)
- Opinion outside EU - Risk-management-plan summary(11)
- Opinion outside EU - Scientific discussion(4)
- Opinion outside EU - Summary for the public(15)
- Opinion outside EU - Summary of opinion(3)
- Opinion outside EU - Summary of opinion - Initial authorisation(9)
- Opinion outside EU - Withdrawal assessment report(1)
- Orphan designation(2420)
- Orphan review(106)
- Other(4049)
- Overview of comments(330)
- Parallel distribution(1)
- Periodic safety update single assessment(2753)
- PIP - Notification of discontinuation of a paediatric development which is covered by an agreed PIP decision(109)
- PIP - Paediatric-investigation-plan summary(93)
- PIP decision(5475)
- Position statement(29)
- PRAC recommendation on signal(164)
- Presentation(5304)
- Press Release(1708)
- Procurement(73)
- Public Statement(485)
- Recommendation on medication errors(26)
- Recruitment(38)
- Referrals document(2764)
- Regulatory and procedural guideline(722)
- Report(1616)
- Scientific guideline(2464)
- Standard Operating Procedure - SOP(129)
- Summary of opinion(1224)
- Summary of opinion - Initial authorisation(1671)
- Supply shortage(58)
- Template or form(479)
- Withdrawal letter(290)
- Work Instruction - WIN(61)
- Work programme(151)
- Advanced therapies(1796)
- Antimicrobial resistance(270)
- Biologicals(147)
- Biosimilars(649)
- Brexit(121)
- Careers(5)
- Clinical trials(586)
- Compassionate use(16)
- Compliance and inspections(600)
- Corporate(111)
- COVID-19(898)
- Data on medicines(988)
- Early access(200)
- Fees(24)
- Generic and hybrid medicines(2176)
- Governance(675)
- Innovation(1164)
- Maximum residue limit(1001)
- Medication error(28)
- Medicines(46944)
- Medicines for use outside the EU(148)
- Medicine shortages(296)
- Mpox(39)
- Paediatrics(12234)
- Parallel distribution(15)
- Pharmacovigilance(9539)
- Procurement(132)
- Product information(6319)
- Quality of medicines(222)
- Rare diseases(8241)
- Referrals(3374)
- Regulatory and procedural guidance(3518)
- Research and development(494)
- Scientific advice(289)
- Scientific guidelines(1739)
- SME(259)
- Vaccines(1500)
- Veterinary limited markets(64)
Search results (84229)
Ryzodeg : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (227.83 KB - PDF)
Tasigna : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (414.92 KB - PDF)
Brukinsa : EPAR - Medicine overview
English (EN) (150.83 KB - PDF)
български (BG) (177.08 KB - PDF)
español (ES) (151.29 KB - PDF)
čeština (CS) (175.09 KB - PDF)
dansk (DA) (149.91 KB - PDF)
Deutsch (DE) (153.26 KB - PDF)
eesti keel (ET) (146.79 KB - PDF)
ελληνικά (EL) (177.79 KB - PDF)
français (FR) (152.61 KB - PDF)
hrvatski (HR) (174.64 KB - PDF)
italiano (IT) (149.75 KB - PDF)
latviešu valoda (LV) (182.18 KB - PDF)
lietuvių kalba (LT) (174.46 KB - PDF)
magyar (HU) (175.79 KB - PDF)
Malti (MT) (175.84 KB - PDF)
Nederlands (NL) (150.06 KB - PDF)
polski (PL) (178.44 KB - PDF)
português (PT) (151.45 KB - PDF)
română (RO) (173.39 KB - PDF)
slovenčina (SK) (174.58 KB - PDF)
slovenščina (SL) (172.87 KB - PDF)
Suomi (FI) (148.53 KB - PDF)
svenska (SV) (148.64 KB - PDF)
Ibrance : EPAR - Product Information
English (EN) (1.59 MB - PDF)
български (BG) (659.71 KB - PDF)
español (ES) (621.56 KB - PDF)
čeština (CS) (657.61 KB - PDF)
dansk (DA) (563.46 KB - PDF)
Deutsch (DE) (626.09 KB - PDF)
eesti keel (ET) (564.75 KB - PDF)
ελληνικά (EL) (627.6 KB - PDF)
français (FR) (630.99 KB - PDF)
hrvatski (HR) (633.89 KB - PDF)
íslenska (IS) (797.94 KB - PDF)
italiano (IT) (825.55 KB - PDF)
latviešu valoda (LV) (745.82 KB - PDF)
lietuvių kalba (LT) (597.56 KB - PDF)
magyar (HU) (667.85 KB - PDF)
Malti (MT) (697.63 KB - PDF)
Nederlands (NL) (589.63 KB - PDF)
norsk (NO) (596.05 KB - PDF)
polski (PL) (577.45 KB - PDF)
português (PT) (615 KB - PDF)
română (RO) (619.39 KB - PDF)
slovenčina (SK) (665.17 KB - PDF)
slovenščina (SL) (620.11 KB - PDF)
Suomi (FI) (2.03 MB - PDF)
svenska (SV) (883.17 KB - PDF)
Ibrance : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (169.88 KB - PDF)
Policy 78: EMA environmental policy
As an EU body the European Medicines Agency acknowledges its institutional responsibility to safeguard the environment for present and future generations. Recognising that social and civil responsibilities of the Agency’s activities have the potential to affect the environment, we believe that a long term sustainable approach and proactive environmental management generates environmental, social and economic value for the community in which it operates.
English (EN) (243.11 KB - PDF)
Kaftrio : EPAR - Product information
English (EN) (835.33 KB - PDF)
български (BG) (1.03 MB - PDF)
español (ES) (842.34 KB - PDF)
čeština (CS) (1.01 MB - PDF)
dansk (DA) (885.33 KB - PDF)
Deutsch (DE) (931.26 KB - PDF)
eesti keel (ET) (917.8 KB - PDF)
ελληνικά (EL) (993.97 KB - PDF)
français (FR) (941.82 KB - PDF)
hrvatski (HR) (973.04 KB - PDF)
íslenska (IS) (879.35 KB - PDF)
italiano (IT) (839.34 KB - PDF)
latviešu valoda (LV) (883.41 KB - PDF)
lietuvių kalba (LT) (916.22 KB - PDF)
magyar (HU) (947.97 KB - PDF)
Malti (MT) (1010.46 KB - PDF)
Nederlands (NL) (804.63 KB - PDF)
norsk (NO) (809.29 KB - PDF)
polski (PL) (973.04 KB - PDF)
português (PT) (893.04 KB - PDF)
română (RO) (979.17 KB - PDF)
slovenčina (SK) (1012.98 KB - PDF)
slovenščina (SL) (913.72 KB - PDF)
Suomi (FI) (872.08 KB - PDF)
svenska (SV) (871.51 KB - PDF)
Kaftrio : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (181.33 KB - PDF)